People · Operator
Named in public records as an officer, director or promoter · active 2015–2022 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Pulmatrix, Inc. | — | Pharmaceuticals | Series B | $62.9M | $86.1M | 2015 |
| Spectrum Antimicrobials, Inc. | — | Pharmaceuticals | Series A | $17.3M | $47.3M | 2020 |
| Collidion Inc. | — | Pharmaceuticals | Series A | $14.5M | $8.5M | 2016 |
Sameer Harish at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Sameer Harish on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Hojabr Alimi | 3 | 3 |
| William H. Watson | 2 | 2 |
| Steven Gillis | 1 | 23 |
| SCOTT ROCKLAGE | 1 | 9 |
| Terrance McGuire | 1 | 9 |
| Michael Higgins | 1 | 9 |
| Robert Clarke | 1 | 7 |
| Kurt Graves | 1 | 5 |
| Amit Munshi | 1 | 5 |
| Mark Iwicki | 1 | 4 |
| MICHAEL J. HIGGINS | 1 | 4 |
| Matthew Sherman | 1 | 3 |
| Richard Zimmer | 1 | 3 |
| William Duke | 1 | 2 |
| David Hava | 1 | 2 |
| David Maki | 1 | 2 |
| JAMES ROACH | 1 | 2 |
| Gregg Alton | 1 | 2 |
| Richard Conley | 1 | 2 |
| Akihisa Akao | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.